November 8, 2010 - SCHILLER AG, a leading international manufacturer and supplier of cardiopulmonary diagnostics and BSP Biological Signal Processing Ltd., a medical device company that develops and markets innovative solutions for noninvasive cardiac diagnosis and monitoring , announced on November 8th, 2010 the signing of an agreement to jointly develop a new product line based on BSP’s HyperQ™ technology. The project will be performed in collaboration with the University Hospital of Basel, one of the premier medical centers in Europe. The project is planned for 3 years with an overall estimated budget of 1.7 Million Euro and will be partly funded by the Swiss and Israeli governments within the prestigious EUROSTARS framework.
The new product line is intended for the lucrative market of resting electrocardiogram (ECG) applications for the early diagnosis and monitoring of myocardial ischemia in patients with suspected acute coronary syndrome, including myocardial infarction (MI). This collaboration comes in continuation to the successful implementation of BSP’s HyperQ™ Analyzer in Schiller's state of the art CS-200 Excellence machine, a system intended for the stress ECG market, which was launched in Medica 2009.
The HyperQ™ technology utilizes advanced signal processing to extract and analyze valuable clinical information from high-resolution ECG signals. Based on solid scientific foundations, and validated in numerous pre-clinical and clinical studies, HyperQ™ provides a novel diagnostic tool for the non-invasive diagnosis of ischemic heart disease, with superior accuracy, compared to conventional ECG... BSP's Press Release -
